PASSAGE BIO INC. - COMMON STOCK

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

24 фев 2023 07:00:52 Источник Nasdaq GlobeNewswire

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

15 фев 2023 07:00:18 Источник Nasdaq GlobeNewswire

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 янв 2023 16:01:55 Источник Nasdaq GlobeNewswire

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

14 дек 2022 07:00:25 Источник Nasdaq GlobeNewswire

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

10 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day

08 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

03 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 окт 2022 16:01:00 Источник Nasdaq GlobeNewswire

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

10 окт 2022 07:00:00 Источник Nasdaq GlobeNewswire

Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference

26 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

19 авг 2022 16:01:00 Источник Nasdaq GlobeNewswire

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

11 авг 2022 07:00:02 Источник Nasdaq GlobeNewswire

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

05 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

04 авг 2022 07:00:03 Источник Nasdaq GlobeNewswire

Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

28 июл 2022 07:30:00 Источник Nasdaq GlobeNewswire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21 июл 2022 16:01:00 Источник Nasdaq GlobeNewswire

Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors

06 июл 2022 07:00:00 Источник Nasdaq GlobeNewswire

Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

09 июн 2022 07:30:00 Источник Nasdaq GlobeNewswire

Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

08 июн 2022 07:30:00 Источник Nasdaq GlobeNewswire

Passage Bio Announces Leadership Transition

01 июн 2022 07:30:00 Источник Nasdaq GlobeNewswire